Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma
Fudan University · Cancer Institute (WIA) · +8 more institutions
Abstract
Abstract Background The efficacy of immune checkpoint blockade therapy in patients with hepatocellular carcinoma (HCC) remains poor. Although serine‐ and arginine‐rich splicing factor (SRSF) family members play crucial roles in tumors, their impact on tumor immunology remains unclear. This study aimed to elucidate the role of SRSF10 in HCC immunotherapy. Methods To identify the key genes associated with immunotherapy resistance, we conducted single‐nuclear RNA sequencing, multiplex immunofluorescence, and The Cancer Genome Atlas and Gene Expression Omnibus database analyses. We investigated the biological functions of SRSF10 in immune evasion using in vitro co‐culture systems, flow cytometry, various…
Citation impact
- FWCI
- 29.94
- Percentile
- 100%
- References
- 60
Authors
15- JCJialiang Cai
Fudan University, Cancer Institute (WIA), Zhongshan Hospital, State Key Laboratory of Genetic Engineering
- LSLina Song
Fudan University, Cancer Institute (WIA), Zhongshan Hospital, State Key Laboratory of Genetic Engineering
- FZFeng Zhang
Fudan University, Zhongshan Hospital, Shanghai Institute of Hematology
- SWSuiyi Wu
Fudan University, Cancer Institute (WIA), Zhongshan Hospital
- GZGui‐Qi Zhu
Academy of Medical Sciences, Sun Yat-sen University, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University, Zhongshan Hospital, Cancer Research Center, The First Affiliated Hospital, Sun Yat-sen University, State Key Laboratory of Genetic Engineering
Topics & keywords
- Lactate dehydrogenase A
- Tumor microenvironment
- Cancer research
- Macrophage polarization
- GLUT1
- Biology
- Immune system
- Immunotherapy
- No poverty